Tyrosine Kinase Inhibitors

Pazopanib. The U.S. Food and Drug Administration approved pazopanib for use in patients with recurrent soft tissue sarcoma. The clinical trial that led to the approval was limited to adults. The study demonstrated disease stabilization and prolonged time to progression; it did not demonstrate improved overall survival.[11]

Pazopanib. The U.S. Food and Drug Administration approved pazopanib for use in patients with recurrent soft tissue sarcoma. The clinical trial that led to the approval was limited to adults. The study demonstrated disease stabilization and prolonged time to progression; it did not demonstrate improved overall survival.[11]

A phase I trial of pazopanib reported one partial response in a patient with desmoplastic small round cell tumor and prolonged disease stabilization in eight patients with recurrent sarcomas.[12][Level of evidence B4]

Pazopanib. The U.S. Food and Drug Administration approved pazopanib for use in patients with recurrent soft tissue sarcoma. The clinical trial that led to the approval was limited to adults. The study demonstrated disease stabilization and prolonged time to progression; it did not demonstrate improved overall survival.[11]

One 13-year-old boy and one 14-year-old girl with multiply recurrent synovial sarcoma and lung metastases had responses to pazopanib for 14 and 15 months, respectively.[13][Level of evidence C2]